Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Randomized, Modified Double-blind, Parallel-group, Active-controlled, Multi-arm, Dose-escalation Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

NCT05426174 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT05426174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05426174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Randomized, Modified Double-blind, Parallel-group, Active-controlled, Multi-arm, Dose-escalation Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 1
Overall status
Completed
Start date
June 9, 2022
Completion date
January 3, 2024
Enrollment
233 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, influenza immunization